Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Reuters

2025/11/07

Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Overview

SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year
Company attributes revenue decline to lower product sales, especially TPOXX deliveries
SIGA focuses on securing new procurement contracts for future revenue growth

Outlook

SIGA focuses on securing new procurement contracts for future revenue growth

Result Drivers

LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries
U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries
INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$6.40 mln

Analyst Coverage

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7g5NW3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581486500"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581486500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581486500?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581486500","market":"fut","top_or_hot":-1,"title":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIGA","symbol_name":"SIGA Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I2:1","article_id":"2581486500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581486500","pubTimestamp":1762463630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SIGA":"SIGA Technologies Inc","BK4007":"制药","BK4583":"猴痘概念"},"translate_title":"抗病毒疗法开发商SIGA第三季度收入因TPOXX交付量下降而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":0.9},"content_text":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompany attributes revenue decline to lower product sales, especially TPOXX deliveriesSIGA focuses on securing new procurement contracts for future revenue growthOutlookSIGA focuses on securing new procurement contracts for future revenue growthResult DriversLOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveriesU.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveriesINTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six yearsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$6.40 mlnAnalyst CoverageThe stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months agoPress Release: ID:nGNX7g5NW3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}